CoolAdvantage BRZ-AP2-160-000Recalls & reported problems
Zeltiq Aesthetics, Inc. · CoolAdvantage Applicator · Class 2
Data updated Oct 18, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 2
- Deaths reported
- 0
- Injuries reported
- 2
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 2 adverse event reports that list this exact device (DI 00816417020575), received between Jan 18, 2019 and Aug 3, 2023 — classified as 2 injuries.
The most frequently reported specific device problem is “Insufficient Device Problem Information” (1 report).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.
Most reported problems
Device problems
- Adverse Event Without Identified Device or Use Problem2
- Insufficient Device Problem Information1
Patient problems
- Hyperplasia1
- Necrosis1
Recent adverse event reports
The 2 most recent of 2 reports, in the reporter's own words as published by the FDA.
InjuryAug 3, 2023Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem
ALLERGAN AESTHETICS RECEIVED A REPORT OF A PATIENT TREATED WITH COOLSCULPTING TO THE UPPER ABDOMEN AND LOWER ABDOMEN ON (B)(6) 2017 USING COOLADVANTAGE COOLCORE CONTOUR WHO DEVELOPED PARADOXICAL HYPERPLASIA (PAH/PH) SIX MONTHS AFTER TREATMENT AND WAS DIAGNOSED WITH PH TO THE LOWER ABDOMEN. PH WAS DESCRIBED AS FIRM/HARD.
Patient problems: Hyperplasia
MAUDE report 17454901 ↗InjuryJan 18, 2019Adverse Event Without Identified Device or Use Problem; Insufficient Device Problem Information; Adverse Event Without Identified Device or Use Problem; Insufficient Device Problem Information
ON (B)(6) 2017, ALLERGAN RECEIVED REPORT FROM A TREATMENT PROVIDER THAT A PATIENT RECEIVED 6 COOLSCULPTING TREATMENTS TO THE UPPER AND LOWER ABDOMEN AND BILATERAL FLANKS ON (B)(6) 2017 AND HAD PRESENTED WITH REDNESS, WARMTH AND PAIN ON THE TREATED AREAS 4 DAYS AFTER TREATMENT. THE PATIENT WAS PRESCRIBED CLINDAMYCIN 300MG TID FOR 10 DAYS, AND BACTROBAN TOPICAL OINTMENT TO BE APPLIED TO THE AFFECTED AREA EVERY 8 HOURS FOR 3-5 DAYS. ON (B)(6) 2017, THE PATIENT WAS SUBSEQUENTLY HOSPITALIZED FOR A FEVER OF 103 DEGREES. HE REMAINED IN THE HOSPITAL FOR FIVE DAYS AND WAS TREATED WITH IV ANTIBIOTICS, PAIN MEDICATION, AND STEROIDS. A BIOPSY WAS PERFORMED AND SHOWED NON-BACTERIAL TISSUE NECROSIS.
Patient problems: Necrosis
MAUDE report 8262725 ↗
Other Dermal Cooling Pack/Vacuum/Massager devices
- CoolSculpting Control Unit BRZ-CG1-CUD-110Zeltiq Aesthetics, Inc. · Dermal Cooling Pack/Vacuum/Massager1 death2,595 reports
- CoolSculpting Elite Control Unit CS-S3-002-D-00Zeltiq Aesthetics, Inc. · Dermal Cooling Pack/Vacuum/Massager1 recall207 reports
- CoolCore BRZ-AP1-063-000Zeltiq Aesthetics, Inc. · Dermal Cooling Pack/Vacuum/Massager1 recall12 reports
- CoolMax Applicator BRZ-AP1-080-000Zeltiq Aesthetics, Inc. · Dermal Cooling Pack/Vacuum/Massager1 recall11 reports
- CoolCurve Applicator BRZ-AP1-062-000Zeltiq Aesthetics, Inc. · Dermal Cooling Pack/Vacuum/Massager1 recall2 reports
- CoolFit BRZ-AP1-066-000Zeltiq Aesthetics, Inc. · Dermal Cooling Pack/Vacuum/Massager1 recall1 report
- CoolCurve+ Applicator BRZ-AP1-064-000Zeltiq Aesthetics, Inc. · Dermal Cooling Pack/Vacuum/Massager1 recall1 report
- CoolSculpting System Applicator Surface 150 (S150) CS-A3-15S-00Zeltiq Aesthetics, Inc. · Dermal Cooling Pack/Vacuum/Massager1 recall0 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 18, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page